Breast Cancer
News
Tumor surroundings may hold key to TNBC treatment optimization
Investigators say their retrospective study results demonstrate that each TNBC subtype is associated with specific tumor microenvironment profiles...
News
Though metastatic breast cancer survival is improving, rates vary by region
A lag in survival improvement across different regions suggests that some groups and regions may benefit unequally from treatment advances as well...
Conference Coverage
New data further define role of PD-L1 status, immunotherapy in metastatic breast cancer
BARCELONA – PD-L1 status in mTNBC or HER2+ breast cancer appears to identify distinct disease entities with varying likelihood of benefit from...
News
Adding pertuzumab shows benefit in ERBB2-positive breast cancer
Total pathologic complete response rates were significantly higher for patients in the pertuzumab arm (39.3%) compared with the placebo arm (21.8...
Opinion
USPSTF recommendations on risk assessment, genetic counseling, and genetic testing for BRCA-related cancer
They recommend using screening tools focusing on family history that primary care physicians can utilize to determine who should be referred for...
News
Trastuzumab benefit lasts long-term in HER2+ breast cancer
The benefit of trastuzumab was greater among patients with HR+ disease than those with HR– disease until the 5-year timepoint, after which HR...
Conference Coverage
Adding veliparib to chemotherapy improves PFS in BRCA-mutated breast cancer
BARCELONA – Adding veliparib to chemotherapy improved PFS and provided more durable benefit than did chemotherapy...
News
Risk of contralateral breast cancer highest for women under 40
Investigators predict 28% of the increased risk of contralateral breast cancer was attributable to stray radiation exposure.
News
Multigene testing for all patients with breast cancer may be cost-effective, life-saving
Modeling suggests high-risk multigene testing for all breast cancer patients might be cost-effective, but critics suggest “true costs are hidden...
Conference Coverage
Ribociclib/fulvestrant boosts survival in advanced breast cancer
BARCELONA – The median overall survival for patients who received the CDK4/6 inhibitor plus fulvestrant has not been reached in the MONALEESA-3...